Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
12:00pm, Monday, 06'th Jan 2020
DURHAM, N.C., Jan. 06, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,.
The ups and downs for stocks of Triangle drugmakers in 2019
08:15pm, Tuesday, 31'st Dec 2019
Despite a strong economy and promising therapeutic candidates, many public companies in the Triangle's life sciences sector saw a difficult year in terms of their stock price while other companies mad
Triangle life science companies net $1.7 billion in 2019
12:25pm, Tuesday, 31'st Dec 2019
Despite many public drugmakers in the Triangle struggling this year, the industry managed to bring in over $1.7 billion in new investments. The total sum came from a mix of federal, public and privat
W2O acquires med comms agency Arcus Medica -
07:59am, Wednesday, 16'th Oct 2019
Healthcare marketing communications agency W2O has acquired Philadelphia’s Arcus Medica to boost its scientific and med comms offering
A Base Editing IPO from Beam Therapeutics
05:59am, Tuesday, 01'st Oct 2019
The ability to modify genes may be one of the most promising disruptive technologies there is today. As the general public learns about the potential of gene editing, retail investors will be looki
El CEO de esta fintech que lleva recaudados 13 millones de dólares, comparte su visión sobre el proceso para conseguir financiación para tu nueva empresa.
Precision BioSciences Stock Offered in IPO
04:47am, Saturday, 09'th Mar 2019
In our recent article on DNA nanotechnology, we looked at a paper co-authored by George Church that refers to the “staggering” progress being made in gene editing. While it used to be that gene
First-time homebuyer? Here’s what you need to know
09:20pm, Saturday, 06'th Oct 2018
A step-by-step guide to making the biggest purchase of your life.
Precision BioSciences Raises $110M in Series B Funding |FinSMEs
09:56pm, Tuesday, 26'th Jun 2018
Precision BioSciences, a Durham, NC-based biotechnology company, closed a $110M Series B financing. The round was led by ArrowMark Partners.
